Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 26.03 USD -2.58% Market Closed
Market Cap: 1.9B USD
Have any thoughts about
Kiniksa Pharmaceuticals Ltd?
Write Note

Wall Street
Price Targets

KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd

Wall Street analysts forecast KNSA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KNSA is 37.3 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

Lowest
Price Target
30.3 USD
16% Upside
Average
Price Target
37.3 USD
43% Upside
Highest
Price Target
47.25 USD
82% Upside
Kiniksa Pharmaceuticals Ltd Competitors:
Price Targets
TSHA
Taysha Gene Therapies Inc
223% Upside
SBTX
SkinBioTherapeutics PLC
183% Upside
MCRB
Seres Therapeutics Inc
45% Downside
CYTK
Cytokinetics Inc
148% Upside
DBV
DBV Technologies SA
171% Upside
MAAT
Maat Pharma SA
239% Upside
ASMB
Assembly Biosciences Inc
183% Upside
VTGN
VistaGen Therapeutics Inc
467% Upside

Revenue
Forecast

Revenue Estimate
Kiniksa Pharmaceuticals Ltd

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is 26%.

N/A
Past Growth
26%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KNSA's stock price target?
Price Target
37.3 USD

According to Wall Street analysts, the average 1-year price target for KNSA is 37.3 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

What is Kiniksa Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
26%

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is 26%.

Back to Top